Inhibition of acid sphingomyelinase increases regulatory T cells in humans. Issue 2 (5th March 2021)
- Record Type:
- Journal Article
- Title:
- Inhibition of acid sphingomyelinase increases regulatory T cells in humans. Issue 2 (5th March 2021)
- Main Title:
- Inhibition of acid sphingomyelinase increases regulatory T cells in humans
- Authors:
- Wiese, Teresa
Dennstädt, Fabio
Hollmann, Claudia
Stonawski, Saskia
Wurst, Catherina
Fink, Julian
Gorte, Erika
Mandasari, Putri
Domschke, Katharina
Hommers, Leif
Vanhove, Bernard
Schumacher, Fabian
Kleuser, Burkhard
Seibel, Jürgen
Rohr, Jan
Buttmann, Mathias
Menke, Andreas
Schneider-Schaulies, Jürgen
Beyersdorf, Niklas - Abstract:
- Abstract: Genetic deficiency for acid sphingomyelinase or its pharmacological inhibition has been shown to increase Foxp3 + regulatory T-cell frequencies among CD4 + T cells in mice. We now investigated whether pharmacological targeting of the acid sphingomyelinase, which catalyzes the cleavage of sphingomyelin to ceramide and phosphorylcholine, also allows to manipulate relative CD4 + Foxp3 + regulatory T-cell frequencies in humans. Pharmacological acid sphingomyelinase inhibition with antidepressants like sertraline, but not those without an inhibitory effect on acid sphingomyelinase activity like citalopram, increased the frequency of Foxp3 + regulatory T cell among human CD4 + T cells in vitro . In an observational prospective clinical study with patients suffering from major depression, we observed that acid sphingomyelinase-inhibiting antidepressants induced a stronger relative increase in the frequency of CD4 + Foxp3 + regulatory T cells in peripheral blood than acid sphingomyelinase-non- or weakly inhibiting antidepressants. This was particularly true for CD45RA − CD25 high effector CD4 + Foxp3 + regulatory T cells. Mechanistically, our data indicate that the positive effect of acid sphingomyelinase inhibition on CD4 + Foxp3 + regulatory T cells required CD28 co-stimulation, suggesting that enhanced CD28 co-stimulation was the driver of the observed increase in the frequency of Foxp3 + regulatory T cells among human CD4 + T cells. In summary, the widely inducedAbstract: Genetic deficiency for acid sphingomyelinase or its pharmacological inhibition has been shown to increase Foxp3 + regulatory T-cell frequencies among CD4 + T cells in mice. We now investigated whether pharmacological targeting of the acid sphingomyelinase, which catalyzes the cleavage of sphingomyelin to ceramide and phosphorylcholine, also allows to manipulate relative CD4 + Foxp3 + regulatory T-cell frequencies in humans. Pharmacological acid sphingomyelinase inhibition with antidepressants like sertraline, but not those without an inhibitory effect on acid sphingomyelinase activity like citalopram, increased the frequency of Foxp3 + regulatory T cell among human CD4 + T cells in vitro . In an observational prospective clinical study with patients suffering from major depression, we observed that acid sphingomyelinase-inhibiting antidepressants induced a stronger relative increase in the frequency of CD4 + Foxp3 + regulatory T cells in peripheral blood than acid sphingomyelinase-non- or weakly inhibiting antidepressants. This was particularly true for CD45RA − CD25 high effector CD4 + Foxp3 + regulatory T cells. Mechanistically, our data indicate that the positive effect of acid sphingomyelinase inhibition on CD4 + Foxp3 + regulatory T cells required CD28 co-stimulation, suggesting that enhanced CD28 co-stimulation was the driver of the observed increase in the frequency of Foxp3 + regulatory T cells among human CD4 + T cells. In summary, the widely induced pharmacological inhibition of acid sphingomyelinase activity in patients leads to an increase in Foxp3 + regulatory T-cell frequencies among CD4 + T cells in humans both in vivo and in vitro . Abstract : In their study, Wiese et al. found that pharmacological inhibition of acid sphingomyelinase with antidepressants such as sertraline or amitriptyline increased the proportion of Foxp3 + regulatory T cells among human CD4 + T cells both in cell culture in vitro as well as in vivo in patients treated for major depression. Graphical Abstract: … (more)
- Is Part Of:
- Brain communications. Volume 3:Issue 2(2021)
- Journal:
- Brain communications
- Issue:
- Volume 3:Issue 2(2021)
- Issue Display:
- Volume 3, Issue 2 (2021)
- Year:
- 2021
- Volume:
- 3
- Issue:
- 2
- Issue Sort Value:
- 2021-0003-0002-0000
- Page Start:
- Page End:
- Publication Date:
- 2021-03-05
- Subjects:
- acid sphingomyelinase -- regulatory T cells -- antidepressants -- sphingolipids -- major depression
616 - Journal URLs:
- https://academic.oup.com/braincomms ↗
http://www.oxfordjournals.org/ ↗ - DOI:
- 10.1093/braincomms/fcab020 ↗
- Languages:
- English
- ISSNs:
- 2632-1297
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 25013.xml